| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Oncology [P. S., H. J.] and Clinical Chemistry [A. O.], Helsinki University Central Hospital, FIN-00029 Hyks, Finland
Vascular endothelial growth factor (VEGF) is a secreted endothelial cell-specific mitogen and permeability factor. Malignant human tumors have been shown to produce VEGF. Elevated levels of VEGF have been detected in sera of cancer patients, but its origin is unsettled. We analyzed VEGF concentrations in serum, plasma, whole blood, and peripheral blood mononuclear cells (PBMNCs) and platelets in 56 cancer patients and 52 healthy controls using ELISA. The VEGF concentrations in the lysed whole blood samples [blood VEGF (B-VEGF)] were higher in cancer patients than in healthy controls (median, 464 versus 298 pg/ml; P < 0.0001). The highest B-VEGF values were found in disseminated cancer. In cancer patients, a high B-VEGF concentration was associated with a high peripheral blood leukocyte count (P = 0.0012) and platelet count (P = 0.019). In healthy individuals, a high B-VEGF was associated with a high leukocyte count (P = 0.0001) but not with the platelet count (P > 0.1). The cancer patients regularly had higher B-VEGF concentrations than healthy individuals with comparable leukocyte or platelet counts. The VEGF content of isolated PBMNCs and platelets was severalfold higher in cancer patients than in healthy controls (median, 10.6 versus 0.9 pg per 106 PBMNCs, and median, 1.6 versus 0.5 pg per 106 platelets; P < 0.0001 and P = 0.0008, respectively). Serum VEGF and B-VEGF correlated strongly (P < 0.0001). Very little or no VEGF was found in the plasma. The results indicate that VEGF in the bloodstream is transported by blood cells, including leukocytes and platelets. The blood cells of cancer patients contain greatly elevated amounts of this major angiogenic growth factor, and this reservoir of VEGF may have a role in tumor angiogenesis and metastasis formation. VEGF in serum samples originates from blood cells, and the use of VEGF of whole blood or of isolated blood cells may improve the clinical value of VEGF measurements.
This article has been cited by other articles:
|
|
 |
|
  G. H. Kim, D. K. Hahn, C. P. Kellner, Z. L. Hickman, R. J. Komotar, R. M. Starke, W. J. Mack, J. Mocco, R. A. Solomon, and E. S. Connolly Jr Plasma Levels of Vascular Endothelial Growth Factor After Treatment for Cerebral Arteriovenous Malformations Stroke, August 1, 2008; 39(8): 2274 - 2279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Purhonen, J. Palm, D. Rossi, N. Kaskenpaa, I. Rajantie, S. Yla-Herttuala, K. Alitalo, I. L. Weissman, and P. Salven Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth PNAS, May 6, 2008; 105(18): 6620 - 6625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, M. Ji, W. Wang, Z. Miao, P. Hou, X. Chen, F. Xu, G. Zhu, X. Sun, Y. Li, et al. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer Endocr. Relat. Cancer, March 1, 2008; 15(1): 183 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kunita, T. G. Kashima, Y. Morishita, M. Fukayama, Y. Kato, T. Tsuruo, and N. Fujita The Platelet Aggregation-Inducing Factor Aggrus/Podoplanin Promotes Pulmonary Metastasis Am. J. Pathol., April 1, 2007; 170(4): 1337 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Manau, F. Fabregues, J. Penarrubia, M. Creus, F. Carmona, G. Casals, W. Jimenez, and J. Balasch Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF Hum. Reprod., March 1, 2007; 22(3): 669 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Kindler, G. Friberg, D. A. Singh, G. Locker, S. Nattam, M. Kozloff, D. A. Taber, T. Karrison, A. Dachman, W. M. Stadler, et al. Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer J. Clin. Oncol., November 1, 2005; 23(31): 8033 - 8040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Amano, N. R. Hackett, S. Rafii, and R. G. Crystal Thrombopoietin Gene Transfer-Mediated Enhancement of Angiogenic Responses to Acute Ischemia Circ. Res., August 19, 2005; 97(4): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bono, A. Krause, M. von Mehren, M. C. Heinrich, C. D. Blanke, S. Dimitrijevic, G. D. Demetri, and H. Joensuu Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib Blood, April 15, 2004; 103(8): 2929 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Kim, I. K. Choi, K. H. Park, S. Y. Yoon, S. C. Oh, J. H. Seo, C. W. Choi, B. S. Kim, S. W. Shin, Y. H. Kim, et al. Serum Vascular Endothelial Growth Factor per Platelet Count in Hepatocellular Carcinoma: Correlations with Clinical Parameters and Survival Jpn. J. Clin. Oncol., April 1, 2004; 34(4): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Kraus, H. W. Stallings III, R. C. Yeager, and T. P. Gavin Circulating plasma VEGF response to exercise in sedentary and endurance-trained men J Appl Physiol, April 1, 2004; 96(4): 1445 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hernberg, P. Virkkunen, P. Bono, H. Ahtinen, H. Maenpaa, and H. Joensuu Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma J. Clin. Oncol., October 15, 2003; 21(20): 3770 - 3776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hormbrey, C. Han, A. Roberts, D. A. McGrouther, and A. L. Harris The Relationship of Human Wound Vascular Endothelial Growth Factor (VEGF) After Breast Cancer Surgery to Circulating VEGF and Angiogenesis Clin. Cancer Res., October 1, 2003; 9(12): 4332 - 4339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. W. Verheul and H. M. Pinedo The Importance of Platelet Counts and Their Contents in Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3219 - 3221. [Full Text] [PDF]
|
|
|
|
 |
|
 R. T.-P. Poon, C. P.-Y. Lau, S.-T. Cheung, W.-C. Yu, and S.-T. Fan Quantitative Correlation of Serum Levels and Tumor Expression of Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma Cancer Res., June 15, 2003; 63(12): 3121 - 3126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Barbera-Guillem, J. K. Nyhus, C. C. Wolford, C. R. Friece, and J. W. Sampsel Vascular Endothelial Growth Factor Secretion by Tumor-infiltrating Macrophages Essentially Supports Tumor Angiogenesis, and IgG Immune Complexes Potentiate the Process Cancer Res., December 1, 2002; 62(23): 7042 - 7049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Dvorak Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kamihata, H. Matsubara, T. Nishiue, S. Fujiyama, K. Amano, O. Iba, T. Imada, and T. Iwasaka Improvement of Collateral Perfusion and Regional Function by Implantation of Peripheral Blood Mononuclear Cells Into Ischemic Hibernating Myocardium Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1804 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Iba, H. Matsubara, Y. Nozawa, S. Fujiyama, K. Amano, Y. Mori, H. Kojima, and T. Iwasaka Angiogenesis by Implantation of Peripheral Blood Mononuclear Cells and Platelets Into Ischemic Limbs Circulation, October 8, 2002; 106(15): 2019 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Awata, K. Inoue, S. Kurihara, T. Ohkubo, M. Watanabe, K. Inukai, I. Inoue, and S. Katayama A Common Polymorphism in the 5'-Untranslated Region of the VEGF Gene Is Associated With Diabetic Retinopathy in Type 2 Diabetes Diabetes, May 1, 2002; 51(5): 1635 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Santini, B. Vincenzi, G. Avvisati, G. Dicuonzo, F. Battistoni, M. Gavasci, A. Salerno, V. Denaro, and G. Tonini Pamidronate Induces Modifications of Circulating Angiogenetic Factors in Cancer Patients Clin. Cancer Res., May 1, 2002; 8(5): 1080 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Colleoni, A. Rocca, M. T. Sandri, L. Zorzino, G. Masci, F. Nole, G. Peruzzotti, C. Robertson, L. Orlando, S. Cinieri, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann. Onc., January 19, 2002; 13(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Gargett, F. Lederman, B. Heryanto, L. S. Gambino, and P. A.W. Rogers Focal vascular endothelial growth factor correlates with angiogenesis in human endometrium. Role of intravascular neutrophils Hum. Reprod., June 1, 2001; 16(6): 1065 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-D. Tabone, J. Landman-Parker, B. Arcil, M.-C. Coudert, I. Gerota, M. Benbunan, G. Leverger, and C. Dosquet Are Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Prognostic Indicators in Pediatric Patientswith Malignant Solid Tumors? Clin. Cancer Res., March 1, 2001; 7(3): 538 - 543. [Abstract] [Full Text]
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jurasz, G. Sawicki, M. Duszyk, J. Sawicka, C. Miranda, I. Mayers, and M. W. Radomski Matrix Metalloproteinase 2 in Tumor Cell-induced Platelet Aggregation: Regulation by Nitric Oxide Cancer Res., January 1, 2001; 61(1): 376 - 382. [Abstract] [Full Text]
|
|
|
|
|
|
P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Blood, December 1, 2000; 96(12): 3712 - 3718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. George, S. A. Eccles, M. G. Tutton, A. M. Abulafi, and R. I. Swift Correlation of Plasma and Serum Vascular Endothelial Growth Factor Levels with Platelet Count in Colorectal Cancer: Clinical Evidence of Platelet Scavenging? Clin. Cancer Res., August 1, 2000; 6(8): 3147 - 3152. [Abstract] [Full Text]
|
|
|
|
|
|
J. Adams, P. J. Carder, S. Downey, M. A. Forbes, K. MacLennan, V. Allgar, S. Kaufman, S. Hallam, R. Bicknell, J. J. Walker, et al. Vascular Endothelial Growth Factor (VEGF) in Breast Cancer: Comparison of Plasma, Serum, and Tissue VEGF and Microvessel Density and Effects of Tamoxifen Cancer Res., June 1, 2000; 60(11): 2898 - 2905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gunsilius, A. L. Petzer, G. Gastl, and P. Salven Correspondence re: P. Salven et al., Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor. Clin. Cancer Res., 5: 487-491, 1999. Clin. Cancer Res., October 1, 1999; 5(10): 2978 - 2979. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
